Fresh from a Pfizer buyout, Luca Santarelli’s crew has created a new company — banking new funds and steering their lead drug to a pivotal
Almost exactly 3 years since he joined the biotech startup world as head of Therachon, the high-profile discovery scientist Luca Santarelli is ready to start 2020 with a new company, opening a new chapter with $35 million in financing from some close venture groups and plans that point straight to Phase III later this year while they hunt new development deals.
We knew last spring that Santarelli’s Basel-based biotech was being bought out by Pfizer for up to $810 million. The pharma giant wanted their drug for dwarfism, plucking it out but letting the 20-member team remain in charge of a separate rare disease drug for short bowel syndrome.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,800+ biopharma pros reading Endpoints daily — and it's free.